Last reviewed · How we verify
E7080 capsule
E7080 capsule is a Small molecule drug developed by Eisai Co., Ltd.. It is currently in Phase 2 development. Also known as: lenvatinib, lenvatinib mesilate, lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate.
At a glance
| Generic name | E7080 capsule |
|---|---|
| Also known as | lenvatinib, lenvatinib mesilate, lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate |
| Sponsor | Eisai Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) (PHASE3)
- A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) (PHASE1)
- A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor (PHASE1, PHASE2)
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) (PHASE2)
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) (PHASE3)
- A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension (PHASE3)
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-Immunotherapy (PHASE2)
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E7080 capsule CI brief — competitive landscape report
- E7080 capsule updates RSS · CI watch RSS
- Eisai Co., Ltd. portfolio CI
Frequently asked questions about E7080 capsule
What is E7080 capsule?
E7080 capsule is a Small molecule drug developed by Eisai Co., Ltd..
Who makes E7080 capsule?
E7080 capsule is developed by Eisai Co., Ltd. (see full Eisai Co., Ltd. pipeline at /company/eisai).
Is E7080 capsule also known as anything else?
E7080 capsule is also known as lenvatinib, lenvatinib mesilate, lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate.
What development phase is E7080 capsule in?
E7080 capsule is in Phase 2.
Related
- Manufacturer: Eisai Co., Ltd. — full pipeline
- Also known as: lenvatinib, lenvatinib mesilate, lenvatinib mesylate, 4-[3-Chloro-4-(N'-cyclopropylureido)phenoxy]-7-methoxyquinoline-6-carboxamide methanesulfonate
- Compare: E7080 capsule vs similar drugs
- Pricing: E7080 capsule cost, discount & access